



Republic of the Philippines
Department of Health
CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2021- 024
15 December 2020

**CANCELLATION OF BIDDING FOR THE PROCUREMENT OF HUMAN PAPILLOMA
VIRUS (HPV) VACCINE
IB NO. 2021-007**

WHEREAS, an Open Competitive Bidding for the Procurement of Human Papilloma Virus (HPV) Vaccine was conducted in accordance with Republic Act (RA) 9184 and its 2016 Revised Implementing Rules and Regulations (IRR) through the National Expenditure Program with a Total Approved Budget for the Contract (ABC) of Four Hundred Seventy Six Million Philippine Pesos (PhP476,000,000.00):

| Item No. | Particular | Quantity | Unit | Total ABC (PhP) |
|----------|-------------------------------------|----------|------|-----------------|
| 1 | Human Papilloma Virus (HPV) Vaccine | 700,000 | Dose | 476,000,000.00 |

WHEREAS, Purchase Request (PR) was received from Disease Prevention and Control Bureau (DPCB);

WHEREAS, on 21 October 2020, a Pre-procurement Conference was conducted at 10:00 AM, at the COBAC Conference Room, Department of Health (DOH) to discuss the details of the procurement at hand;

WHEREAS, on 27 October 2020, the Central Office Bids and Awards Committee (COBAC)-A issued a memorandum to DPCB requesting for confirmation on the comments/clarifications as discussed during the Pre-procurement Conference;

WHEREAS, on 29 October 2020, the changes on the PR was countersigned by the End-user's representative;

WHEREAS, on 04 November 2020, the Invitation to Bid (IB) was posted in the PhilGEPS and DOH websites and in conspicuous places within the premises of the DOH for a continuous period of seven (7) calendar days;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2021-340 dated 05 November 2020;

WHEREAS, on 11 November 2020, Bid Bulletin No. 1, dated 11 November 2020 was issued to announce the new schedule of the Pre-bidding Conference and the Submission and Opening of Bids previously set on 12 November 2020 and 25 November 2020, respectively;

WHEREAS, on 18 November 2020, a Pre-bidding Conference took place as re-scheduled at 10:00 AM at the COBAC Conference Room, DOH, with two (2) prospective bidders attending the cited Conference, namely, MSD and Zuellig Pharma Corporation (ZPC);

WHEREAS, during the said Pre-bidding Conference, clarifications on the Eligibility Requirements, Special Conditions of Contract, Schedule of Requirements and Technical Specifications were discussed;

WHEREAS, on 20 November 2020, a clarification letter was received from ZPC;

WHEREAS, on the same date, the Minutes of the Pre-Bidding Conference was posted in the DOH website;

WHEREAS, on 21 November 2020, the letter of ZPC was endorsed to the DPCB for appropriate action;

WHEREAS, on the same date, a memorandum was issued to DPCB based on the comments and suggestions raised during the Pre-Bidding Conference;

WHEREAS, on 25 November 2020, the letter of ZPC was presented to COBAC-A during its 46th COBAC-A Meeting and decided to wait for the response of the DPCB on the request of the bidder for the quantity and unit cost;

WHEREAS, Bid Bulletin No. 2, dated 25 November 2020 was issued to announce the postponement until further notice of the Submission and Opening of Bids previously set on 02 December 2020;

WHEREAS, on 26 November 2020, acknowledgement letter was issued to ZPC through e-mail;

WHEREAS, on the same date, another memorandum was issued to DPCB that serves as final demand for the submission of their response on the comments and suggestions raised during the Pre-Bidding Conference;

WHEREAS, on the same date, a memorandum was received from DPCB requesting to put on hold the project since they will revise the quantities and request Pharmaceutical Division (PD) for the new indicate price of the vaccine;

WHEREAS, on 02 December 2020, the memorandum from DPCB was presented to COBAC-A during its 47th COBAC-A Meeting and noted the information;

WHEREAS, on the same date, another memorandum was received from DPCB still requesting to put on hold the project;

WHEREAS, on 09 December 2020, the memorandum from DPCB was presented to COBAC-A during its 48th COBAC-A Meeting and noted the information;

WHEREAS, during the above-cited conference, the Committee was informed that the maximum period of forty-five (45) calendar days from the last day of posting up to the submission and receipt of bids pursuant to Section 25.5.a of the 2016 Implementing Rules and Regulations (IRR) of RA 9184 is on 18 December 2020 and the response of the End-user if the procurement project will proceed must be received on 11 December 2020;

WHEREAS, the COBAC-A noted the information and decided to issue a memorandum to DPCB informing on the above-cited issue;

WHEREAS, on the same date, the COBAC-A issued a memorandum to DPCB requesting for the submission of their response on 11 December 2020 and the possibility of cancelling the procurement;

WHEREAS, on 11 December 2020, no response was received from DPCB;

WHEREAS, on 15 December 2020, the COBAC-A during its 50th Regular Meeting was informed that no response was received from DPCB last 11 December and upon review and deliberation, the Committee decided to cancel the current procurement process pursuant to GPPB Resolution No. 09-2020 and Section 35.6 of the 2016 Revised IRR, *“the BAC is authorized, upon consultation with the end-user unit, to cancel or terminate the conduct of procurement activities, for any justifiable reasons;*

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A **HEREBY RESOLVE** to recommend the following:


1. Cancellation of current bidding for the item listed below:

| Description | Qty. | Unit | Amount (PhP) |
|--|---------|------|----------------|
| Human Papilloma Virus (HPV) Vaccine | 700,000 | Dose | 476,000,000.00 |

DEC 23 2020

Signed this _____ day of _____ 2020 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) - A


ALELI ANNIE GRACE P. SUDIACAL, MD, MPH, CESE
Regular Member

LEONITA P. GORGOLON, MD, MHA, MCHM, CEO VI
Regular Member


LESTER M. TAN, MD, MPH, Msc
Regular Member


MARIA SOLEDAD Q. ANTONIO, MD, PhD, MPH, DPAFP, CESE
Vice-Chairperson


NESTOR F. SANTIAGO, JR., MD, MPHC, MHSA, CESO II
Assistant Secretary of Health
Chairperson